Communications Biology (Feb 2021)
Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models
- Jack Wuyang Jin,
- Xuelai Fan,
- Esther del Cid-Pellitero,
- Xing-Xing Liu,
- Limin Zhou,
- Chunfang Dai,
- Ebrima Gibbs,
- Wenting He,
- Hongjie Li,
- Xiaobin Wu,
- Austin Hill,
- Blair R. Leavitt,
- Neil Cashman,
- Lidong Liu,
- Jie Lu,
- Thomas M. Durcan,
- Zhifang Dong,
- Edward A. Fon,
- Yu Tian Wang
Affiliations
- Jack Wuyang Jin
- The Djavad Mowafaghian Centre for Brain Health and Department of Medicine, University of British Columbia
- Xuelai Fan
- The Djavad Mowafaghian Centre for Brain Health and Department of Medicine, University of British Columbia
- Esther del Cid-Pellitero
- McGill Parkinson Program, Neurodegenerative Diseases Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University
- Xing-Xing Liu
- McGill Parkinson Program, Neurodegenerative Diseases Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University
- Limin Zhou
- Ministry of Education Key Laboratory of Child Development and Disorders, Children’s Hospital of Chongqing Medical University
- Chunfang Dai
- Ministry of Education Key Laboratory of Child Development and Disorders, Children’s Hospital of Chongqing Medical University
- Ebrima Gibbs
- The Djavad Mowafaghian Centre for Brain Health and Department of Medicine, University of British Columbia
- Wenting He
- Ministry of Education Key Laboratory of Child Development and Disorders, Children’s Hospital of Chongqing Medical University
- Hongjie Li
- Ministry of Education Key Laboratory of Child Development and Disorders, Children’s Hospital of Chongqing Medical University
- Xiaobin Wu
- Ministry of Education Key Laboratory of Child Development and Disorders, Children’s Hospital of Chongqing Medical University
- Austin Hill
- Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics, University of British Columbia
- Blair R. Leavitt
- Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics, University of British Columbia
- Neil Cashman
- The Djavad Mowafaghian Centre for Brain Health and Department of Medicine, University of British Columbia
- Lidong Liu
- The Djavad Mowafaghian Centre for Brain Health and Department of Medicine, University of British Columbia
- Jie Lu
- The Djavad Mowafaghian Centre for Brain Health and Department of Medicine, University of British Columbia
- Thomas M. Durcan
- McGill Parkinson Program, Neurodegenerative Diseases Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University
- Zhifang Dong
- Ministry of Education Key Laboratory of Child Development and Disorders, Children’s Hospital of Chongqing Medical University
- Edward A. Fon
- McGill Parkinson Program, Neurodegenerative Diseases Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University
- Yu Tian Wang
- The Djavad Mowafaghian Centre for Brain Health and Department of Medicine, University of British Columbia
- DOI
- https://doi.org/10.1038/s42003-021-01746-6
- Journal volume & issue
-
Vol. 4,
no. 1
pp. 1 – 15
Abstract
Jin et al develop and characterise a blood-brain barrier and plasma membrane-permeable α-synuclein knockdown peptide, Tat-βsyn-degron. In two mouse models of Parkinson’s disease, they show that Tat-βsyn-degron decreases α-synuclein aggregates and microglial activation as well as reducing neuronal damage and motor impairment. This study demonstrates the therapeutic potential of Tat-βsyn-degron in Parkinson’s disease treatment.
